Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...

Net income attributable to SiteOne decreased $12.9 million to $44.4 million Adjusted EBITDA 1 decreased 4% to $114.8 million; Adjusted EBITDA margin was 9.5% Cash provided by operating activities ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

SiteOne Landscape Supply, Inc., together with its subsidiaries, engages in the wholesale distribution of landscape supplies in the United States and Canada. The company provides irrigation ...

Throughout the last three months, 6 analysts have evaluated SiteOne Landscape Supply (NYSE:SITE), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...